# Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III

> **NCT05141305** · PHASE3 · COMPLETED · sponsor: **Beijing Tiantan Hospital** · enrollment: 516 (actual)

## Conditions studied

- Ischemic Stroke, Acute

## Interventions

- **DRUG:** tenecteplase (0.25 mg/kg, Max 25 mg)
- **DRUG:** standard medical treatment

## Key facts

- **NCT ID:** NCT05141305
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-19
- **Primary completion:** 2024-01-29
- **Final completion:** 2024-02-09
- **Target enrollment:** 516 (ACTUAL)
- **Last updated:** 2024-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05141305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05141305, "Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05141305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*